Kelun-Biotech Phase III Trial Shows PFS Improvement in NSCLC
Kelun-Biotech said the OptiTROP-Lung06 trial met its primary endpoint, with sac-TMT plus pembrolizumab significantly improving progression-free survival versus platinum doublet plus pembrolizumab in first-line patients with PD-L1 below 1% and EGFR/ALK-negative advanced non-squamous NSCLC. Overall survival trended in favor of the combination.
Kelun-Biotech said Phase III OptiTROP-Lung06 met its primary endpoint: sac-TMT plus pembrolizumab significantly improved PFS vs platinum doublet plus pembrolizumab in first-line PD-L1<1%, EGFR/ALK-negative advanced non-squamous NSCLC; OS trend favored the combo.Material DetailsContext by AI Analyst…